144243-24-3

Basic information

• Product Name: 1-BOC-3-AMINOPIPERIDINE
• Synonyms: DL-3-AMINO-1-N-BOC-PIPERIDINE;1-N-BOC-3-AMINOPIPERIDINE;1-PIPERIDINECARBOXYLIC ACID, 3-AMINO-, 1,1-DIMETHYLETHYL ESTER;(+/-)-1-BOC-3-AMINO-PIPERIDINE;1-BOC-3-AMINOPIPERIDINE;3-AMINOPIPERIDINE, N1-BOC PROTECTED;(+/-)-3-AMINO-1-BOC-PIPERIDINE;3-AMINO-1-TERTBUTOXYCARBONYL-PIPERIDINE
• CAS NO: 144243-24-3
• Molecular Formula: C₁₀H₂₀N₂O₂
• Molecular Weight: 200.28
• Product Categories: Amines;blocks;chiral
• Mol File: 144243-24-3.mol

Chemical Properties

• Melting Point: 181-182℃
• Boiling Point: 277.3 °C at 760 mmHg
• Flash Point: 121.5 °C
• Appearance: Colorless to yellow/Liquid
• Density: 1.041 g/cm³
• Vapor Pressure: 0.00456mmHg at 25°C
• CAS DataBase Reference: 1-BOC-3-AMINOPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-3-AMINOPIPERIDINE(144243-24-3)
• EPA Substance Registry System: 1-BOC-3-AMINOPIPERIDINE(144243-24-3)

Safety Data

• Hazard Codes: Xn:Harmful
• Statements: R22:; R36/37/38:
• Safety Statements: S26:
• Hazardous Substances Data: 144243-24-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-BOC-3-aminopiperidine is used as a key intermediate in the synthesis of various drugs for its ability to be easily functionalized after the removal of the BOC protecting group. This feature is crucial for the development of new pharmaceuticals with specific therapeutic properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-BOC-3-aminopiperidine is utilized as a building block for the creation of complex molecular structures that can target specific biological pathways, contributing to the advancement of drug discovery and the development of novel therapeutic agents.
Used in Agrochemicals:
1-BOC-3-aminopiperidine also finds applications in the synthesis of agrochemicals, where its protected amino group can be tailored to create compounds with pesticidal or herbicidal properties, thereby enhancing crop protection and yield.

InChI:InChI=1/C10H20N2O2/c1-10(2,3)14-9(13)12-6-4-5-8(11)7-12/h8H,4-7,11H2,1-3H3/p+1/t8-/m1/s1

Upstream product

• 54012-73-6 3-aminopiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 189321-64-0 C₁₁H₁₈N₂O₃ 
• 129888-60-4 1-(tert-Butoxycarbonyl)-3-(methanesulfonyloxy)piperidine 
• 85275-45-2 N-tert-butoxycarbonyl-3-piperidinol 
• 6859-99-0 3-hydroxypiperazine 
• 129888-61-5 3-Azido-1-(tert-butoxycarbonyl)piperidine 

Downstream Products

• 183207-67-2 1-(tert-butoxycarbonyl)-3-(phenylamino)piperidine 
• 816468-38-9 tert-butyl 3-[(4-methoxyphenyl)amino]piperidine-1-carboxylate 
• 816468-54-9 1-(tert-butoxycarbonyl)-3-(4-fluorophenylamino)piperidine 
• 247568-90-7 2-[1-(tert-butoxycarbonyl)piperidin-3-ylamino]-N-(3,4-dimethoxybenzyl)-5-nitrobenzamide 
• 247569-04-6 2-[1-(tert-butoxycarbonyl)piperidin-3-ylamino]-5-cyano-N-(3,4-dimethoxybenzyl)benzamide 
• 1016538-94-5 C₁₆H₂₃FN₂O₄S 
• 478645-89-5 C₁₇H₂₄N₂O₃ 
• 98977-36-7 3-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 1260242-83-8 C₃₁H₃₅F₆N₇O₂ 

Relevant articles and documents

Optimization of Small Molecules That Sensitize HIV-1 Infected Cells to Antibody-Dependent Cellular Cytotoxicity

With approximately 37 million people living with HIV worldwide and an estimated 2 million new infections reported each year, the need to derive novel strategies aimed at eradicating HIV-1 infection remains a critical worldwide challenge. One potential strategy would involve eliminating infected cells via antibody-dependent cellular cytotoxicity (ADCC). HIV-1 has evolved sophisticated mechanisms to conceal epitopes located in its envelope glycoprotein (Env) that are recognized by ADCC-mediating antibodies present in sera from HIV-1 infected individuals. Our aim is to circumvent this evasion via the development of small molecules that expose relevant anti-Env epitopes and sensitize HIV-1 infected cells to ADCC. Rapid elaboration of an initial screening hit using parallel synthesis and structure-based optimization has led to the development of potent small molecules that elicit this humoral response. Efforts to increase the ADCC activity of this class of small molecules with the aim of increasing their therapeutic potential was based on our recent cocrystal structures with gp120 core.

The synthesis of piperidine nucleoside analogs - A comparison of several methods to access the introduction of nucleobases

This work deals with the synthesis of piperidine and hydroxypiperidine analogs of nucleosides. Starting from commercially available 3-hydroxypiperidine, proline or 4-hydroxyproline, a series of piperidine derivatives of both purine and pyrimidine nucleobases was prepared. Various methods of nucleobase attachment were evaluated. The prepared compounds were tested for cytostatic, antibacterial, and antiviral properties but no significant activity was found.

A modified Curtius reaction: an efficient and simple method for direct isolation of free amine

The Curtius rearrangement and related reactions are often used to convert carboxylic acids to the corresponding primary amines. However, this reaction often requires harsh conditions for hydrolysis of the isocyanate intermediates to amines, and can also be contaminated by the formation of corresponding ureas due to the reactive nature of the intermediates. We have discovered that by quenching the isocyanate intermediates with sodium trimethylsilanolate, the free amines can be isolated after aqueous workup. This mild and fast procedure provides free amines in one pot with good yields.

PROCESS FOR PRODUCING 1-ALKOXYCARBONYL NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE

A method for producing N-protected heterocyclic compounds such as 1-alkoxycarbonyl-3-aminopyrrolidines through position-selective reaction at the nitrogen atom that constitutes the hetero ring of a nitrogen-containing saturated heterocyclic compound having two nitrogen atoms such as 3-aminopyrrolidine. A dialkyl dicarbonate (ROCO-O-COOR) is reacted with a nitrogen-containing saturated heterocyclic compounds having two nitrogen atoms, at pH of from 9 to 14 to obtain a high-purity 1-alkoxycarbonyl nitrogen-containing saturated heterocyclic compound.

Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase

Compounds of formula (I) STR1where R 1 is hydrogen; R 2 is nitro, cyano or halo(lower)alkyl; R 3 is phenyl substituted with one or more substituents selected from halogen, cyano and lower alkoxy; A is a lower alkylene group; R 4 is a group CR 6 R 7 R 8 wherein R 6 and R 7 form, together with the carbon atom to which they are attached a cycloalkyl group optionally substituted with hydroxy, lower alkoxy or a lower alkanoylamino; and R 8 is hydrogen; its prodrug and a salt thereof.

PYRAZINONE, PYRIDINONE, PIPERIDINE AND PYRROLIDINE THROMBIN INHIBITORS

A compound which inhibits human thrombin and where has the structure and pharmaceutically acceptable salts thereof, wherein such as STR1 which are useful for inhibiting formation of blood platelet aggregates in blood in a mammal.

Pyrimido[5,4]-dipyrimidines, pharmaceuticals containing them, their use and processes for the preparation thereof

Pyrimido[5,4-d]pyrimidines of the general formula [Figure] which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of disorders, in particular of oncoses, and their preparation. Exemplary compounds are: 4-[(3-Chloro-4-fluorophenyl)amino]-6-[1-methyl-4-piperidinylamino]pyrimido[5,4-d]pyrimidine, and 4-[(3-Chloro-4-fluorophenyl)amino]-6-[trans-4-dimethyl-aminocycohexylamino]pyrimido[5,4-d]pyrimidine.

NITROGEN-CONTAINING CYCLOHETERO ALKYLAMINO ARYL DEERIVATIVES FOR CNS DISORDERS

Compounds comprising a pyrrolidinyl ring are disclosed for use in the treatment of cerebral ischemia.

Synthesis and Biological Evaluation of Conformationally Restricted 2-(1-Pyrrolidinyl)-N--N-methylethylenediamines as ? Receptor Ligands. 1. Pyrrolidine, Piperidine, Homopiperidine, and Tetrahydroisoquinoline Classes

The synthesis and ? receptor affinity of a series of conformationally restricted derivatives of 2-(1-pyrrolidinyl)-N--N-methylethylenediamine (1) is described.The pyrrolidinyl (or N,N-dialkyl), ethylenediamine, N-alkyl, and phenylethyl portions of this ? receptor pharmacophore were restricted by its incorporation into 1,2-cyclohexanediamine-, pyrrolidine-, piperidine-, homopiperidine-, and tetrahydroisoquinoline-containing ligands.The ? receptor binding affinities of these compounds were determined using (+)-pentazocine in guinea pig brain homogenates.The synthesis of all but one class was achieved by acylation and alane reduction of the appropriate diamine precursors whose synthesis is also reported. ? receptor affinities ranged from 1.34 nM for 6,7-dichloro-2-tetrahydroisoquinoline (12) to 455 nM for (1R,2R)-trans-N--N-methyl-2-(1-pyrrolidinyl)cyclohexylamine .In this displacement assay, (+)-pentazocine exhibited a Ki of 3.1 nM while DTG and haloperidol showed Ki values of 27.7 and 3.7 nM, respectively.The conformationally free parent compound 1 exhibited a Ki value of 2.1 nM.Comparison of both the ? receptor affinities and nitrogen atom geometry of the compounds revealed that a gauche relation of the nitrogen atoms of cis-1,2-cyclohexanediamines is not imperative for high affinity as we had previously thought.It is highly likely that nitrogen lone pair orientations and steric factors on the aliphatic portions of these ligands play a major role in the ? receptor binding of this pharmacophore.